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Bone morphogenetic proteins (BMPs) are members of the
TGFβ growth factor superfamily and have important roles
in proliferation, development, differentiation of embry-
onic and adult cells, as well as in tissue regeneration.
BMPs signal via  two transmembrane serine/threonine
kinase receptors, the BMP type I (BMPRIa and BMPRIb)
and BMP type II (BMPRII) receptors which can form
homo- and heterooligomeric complexes. They occur in
distinct membrane areas, are differently modulated upon
ligand binding and are subsequently endocytosed [1].
Upon ligand binding to the receptor complex a signaling
cascade via Smad proteins or independent of Smads is ini-
tiated and results in expression of specific target genes.
cGMP-dependent kinase I (cGKI) was identified as a
BMPRII interacting protein in a proteomics-based
approach using the cytoplasmic BMPRII-tail region as bait
[2]. cGKI is a cytoplasmic serine/threonine kinase and sig-
nals via the NO/cGMP/cGK pathway and is involved in
regulation of growth, differentiation and apoptosis of
cells [3].
The involvement of cGKI in BMP signaling could be vali-
dated as it positively influences receptor and Smad activa-
tion at the plasma membrane as well as it enhances the
transcription of target genes in the nucleus [4]. New
results hint towards the fact that cGKI is involved in endo-
cytotic events in BMP signaling, as it dynamically interacts
with BMPRII upon BMP-2 stimulation and enhances the
internalization of the receptor. Interfering with endocyto-
sis in the cell inhibits BMP signaling mediated by BMP-2
and cGKI.
Clinical evidence for the involvement of cGKI in BMP-sig-
naling is given by the fact that mutations in the BMPRII
are related to the development of primary arterial hyperten-
sion (PAH) [5]. Patients with PAH suffer from vasocon-
striction and elevated pressure in the pulmonary arteries,
but the distinct pathway leading to the specific phenotype
is still unraveled. We could show that ineffective signaling
caused by mutant BMPRII found in PAH could be com-
pensated through cGKI [4].
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